Melazyme Secures $2M Seed Funding to Pioneer Sustainable Precision Fermentation for Cosmetics

Melazyme, a US biotech startup founded in 2025, has raised $2 million in a seed round led by Thailand-based SeaX Ventures.

The funding round also drew investments from Stellaris Venture Partners and Plug and Play Ventures, earmarked for scaling the company's precision fermentation platform.

Revolutionizing Biomolecule Production

Melazyme's technology uses engineered microbes to produce high-value functional biomolecules, including specialty proteins like brazzein and tunable melanin.

This approach enables melanin with adjustable properties for UV protection and pigmentation, targeting the cosmetics industry first.

A Greener Path in Synthetic Biology

Precision fermentation bypasses energy-intensive chemical processes, offering a sustainable alternative for ingredients traditionally sourced from petrochemicals or rare natural extracts.

The funds will advance platform development, ramp up production, and kickstart commercial partnerships across consumer markets.

SeaX Ventures Managing Partner Dr. Kid Parchariyanon highlighted the founding team's expertise in scaling fermentation tech with multi-industry potential.

In a booming synbio sector valued at billions, Melazyme joins innovators producing collagen and dairy proteins via similar methods.

For everyday consumers, this means access to eco-friendlier sunscreens and makeup that perform better without harming the planet.

Global VC Shifts and Future Impact

SeaX's investment signals rising Southeast Asian VC appetite for US biotech, bridging regions amid climate-driven demand for green tech.

Success could expand Melazyme's portfolio to industrial enzymes and environmental remediation, reshaping supply chains.

With early deployments underway, this funding marks a pivotal step toward mainstream adoption of fermented biomaterials.